TY - JOUR AU - Li, Wen-Yi AU - Chiu, AU - Zeng, Jyun-Kai AU - Li, Yao-Wei AU - Huang, Su-Hua AU - Yeh, Hui-Chin AU - Cheng, borwen AU - Yang, fengjung PY - 2020 DA - 20/12/15 TI -使用社交媒体支持慢性肾病患者自我管理的移动健康应用程序:前瞻性随机对照研究JO - J Med Internet Res SP - e19452 VL - 22 IS - 12kw -慢性肾脏疾病KW -自我管理KW -自我效能KW -生活质量KW -健康管理平台KW -可穿戴设备AB -背景:慢性肾脏疾病(CKD)是全球健康负担。自我管理在改善可改变的风险因素方面起着关键作用。目的:本研究旨在评估可穿戴设备、健康管理平台和社交媒体在改善CKD自我管理方面的有效性，旨在建立一种新的自我管理干预模式。方法:在一项为期90天的前瞻性实验研究中，共有60名1-4期CKD患者被纳入干预组(n=30)和对照组(n=30)。所有参与者都配备了收集运动相关数据的可穿戴设备。所有参与者都使用智能手机应用程序记录饮食日记。所有的饮食和运动信息都被上传到健康管理平台。有关饮食和运动的建议只提供给干预组，并创建了一个社交媒体群来激励干预组的参与者。比较干预组和对照组在干预前后的自我效能感和自我管理问卷评分、肾脏疾病生活质量评分、身体组成和实验室检查。结果:共有49名参与者完成了研究(干预组25人，对照组24人); 74% of the participants were men and the mean age was 51.22 years. There were no differences in measured baseline characteristics between the groups except for educational background. After the intervention, the intervention group showed significantly higher scores for self-efficacy (mean 171.28, SD 22.92 vs mean 142.21, SD 26.36; P<.001) and self-management (mean 54.16, SD 6.71 vs mean 47.58, SD 6.42; P=.001). Kidney Disease Quality of Life scores were also higher in the intervention group (mean 293.16, SD 34.21 vs mean 276.37, SD 32.21; P=.02). The number of steps per day increased in the intervention group (9768.56 in week 1 and 11,389.12 in week 12). The estimated glomerular filtration rate (eGFR) of the intervention group was higher than that of the control group (mean 72.47, SD 24.28 vs mean 59.69, SD 22.25 mL/min/1.73m2; P=.03) and the decline in eGFR was significantly slower in the intervention group (–0.56 vs –4.58 mL/min/1.73m2). There were no differences in body composition between groups postintervention. Conclusions: The use of wearable devices, a health management platform, and social media support not only strengthened self-efficacy and self-management but also improved quality of life and a slower eGFR decline in people with CKD at stages 1-4. These results outline a new self-management model to promote healthy lifestyle behaviors for patients with CKD. Trial Registration: ClinicalTrials.gov NCT04617431; https://www.clinicaltrials.gov/ct2/show/NCT04617431 SN - 1438-8871 UR - //www.mybigtv.com/2020/12/e19452/ UR - https://doi.org/10.2196/19452 UR - http://www.ncbi.nlm.nih.gov/pubmed/33320101 DO - 10.2196/19452 ID - info:doi/10.2196/19452 ER -